An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/ leucovorin

Investigational New Drugs

Volumn 23, Issue 1, 2005, Pages 63-71

  Goel, R ^a   Chouinard, E ^b   Stewart, D J ^a   Huan, S ^a   Hirte, H ^b   Stafford, S ^b   Waterfield, B ^a   Roach, J ^a   Lathia, C ^c   Agarwal, V ^c   Humphrey, R ^c   Walsh, W ^d   Matthews, S ^d   Seymour, L ^d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c BAYER CORPORATION   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 fluorouracil; dosing; matrix metalloproteinase; pharmacokinetics; solid tumors; toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; FLUOROURACIL; FOLINIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; TANOMASTAT;

ADULT; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; ILEITIS; INTESTINE PERFORATION; KIDNEY CARCINOMA; LETHARGY; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TOXICITY; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; COHORT STUDIES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; KIDNEY NEOPLASMS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASES; MAXIMUM TOLERATED DOSE; ORGANIC CHEMICALS; SAFETY; SALVAGE THERAPY;

EID: 20844451559     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000047107.35764.d9     Document Type: Article

References (31)

1. Forget MA, Desrosiers RR, Beliveau R: Physiological roles of matrix metalloproteinases: Implications for tumor growth and metastasis. Can J Physiol & Pharmacol 77(7): 465-480, 1999
2. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Geuring AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A: Preclinical and clinical studies of MMP inhibitors in cancer. Ann New York Acad Sc878: 228-235, 1998
3. Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemotherapy & Pharmacol 43(Suppl): S42-S51, 1999
4. Kahari VM, Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31(1): 34-45, 1999
5. McCawley LJ, Matrisian LM: Matrix metalloproteinases: Multi-functional contributors to tumor progression. Molecular Medicine Today 6(4): 49-56, 2000
6. Yip D, Ahmad A, Karapetis CS, Hawkins CA, Harper PG: Matrix metalloproteinase inhibitors: Applications in oncology. Investigational New Drugs 17(4): 387-399, 1999
7. Kluender H, Dixon B, VanZandt M, Hawkins CA, Harper PG: Substituted 4-biarylbutyric acid derivatives as matrix metalloproteinase inhibitors. U.S. patent 5,861,428 granted to Bayer Corp. Jan. 19, 1999
8. Bull C, Flynn C, Eberwein D, Casazza AM, Carter CA, Hibner B: Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models (Abstract) Proc Am Assoc Cancer Res 39: 302, 1998
9. Flynn C, Bull C, Matherne C, Eberwein N, Gibson B, Hibner B: Anti-invasive and anti-metastatic activity of the novel MMP inhibitor BAY 12-9566 in subcutaneous and orthotopic models using the human colon carcinoma, HCT 116. (Abstract) Annals Oncol 9 (suppl 2): 75, 1998
10. Nozaki S, Sissons S, Casazza AM, Sledge GW: Inhibition of human breast cancer regrowth and pulmonary metastases by BAY 12-9566 in athymic mice. (Abstract) Proc Am Assoc Cancer Res 39: 301, 1998
11. Hibner B, Gard A, Flynn C, Casazza AM, Taraboletti G, Rieppi M, Glavazzi R: BAY 12-9566, a novel biphenyl matrix metalloproteinase inhibitor demonstrates anti-invasive and anti-angiogenic properties. (Abstract) Proc Am Assoc Cancer Res 39: 302, 1998
12. Brubaker WF, Perrino P, Wu W, Jaworski S, Town C, Jones L, Ward D, Chien DS: Pharmacokinetics of BAY 12-9566 in animals: species comparisons. (Abstract) Proc Am Assoc Cancer Res 40: 391, 1991
13. Clemens GR, Detzer K, Bomhard E, von Keutz E: Preclinical drug safety profile for the anti-metastatic matrix metalloproteinase inhibitory agent BAY 12-9566. (Abstract) Ann Oncol 9(suppl 2):74 1998
14. Shah A, Sundaresan P, Humphrey R, Heller AH: Comparative pharmacokinetics of BAY 12-9566, a metalloproteinase inhibitor, in healthy volunteers and cancer patients. (Abstract) Proc Am Assoc Cancer Res 30: 521, 1998.
15. Hirte H, Goel R, Major P, Seymour L, Huan S, Stewart D, Yau J, Arnold A, Holohan S, Waterfield B, Bates S, Bennett K, Walsh W, Elias I: A Phase I Dose Escalation Study of the Matrix Metalloproteinase Inhibitor BAY 12-9566 Administered Orally in Patients with Advanced Solid Tumours. Annals Oncol 1579-1584, 2000
16. Rowinsky E, Humphrey R, Hamond LA, Aylesworth C, Smetzer L, Hidalgo M, Marrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG: Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 18: 178-186, 2000
17. Heath EI, O'Reilly S, Humphrey R, Sundarasen P, Donehoweer RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Growchow LB: Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48: 265-274, 2001
18. Erlichman C, Adjei A, Alberts S, Sloan JA, Goldberg RM, Pilot HC, Rubin J, Atherton PJ, Klee GG, Humphrey R: Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 12: 389-395, 2001
19. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gertsner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991
20. International multicentre pooled analysis of colon cancer trials (IMPACT) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939-944, 1995
21. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal Cg, Mailliard JA: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 2: 14-20, 1994
22. Moertel CG: Chemotherapy for colorectal cancer. New England J Med 330(16): 1136-1141, 1994
23. Sobrero AF: Fluorouracil in colorectal cancer - a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15: 368-381, 1997
24. Brundage M, Pater J, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 85: 1138-1148, 1993
25. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
26. Agarwal V, Rose D, Krol G: Quantitative HPLC analysis of 4-[4-4-(Chlorophenyl)phenyl]-4-oxo-2S-(phenylthiomethyl)butanoic acid (BAY 12-9566), a metalloproteinase inhibitor, and its metabolites in human plasma. Journal of Liquid Chromatography and Related Technologies 22: 1893-106, 1999
27. Coe RA, Earl RA, Johnson TC, Lee JW: Determination of 5-fluorouracil in human plasma by a simple and sensitive reverse-phase HPLC method. J. Pharm Biomed Anal 14: 1773-1741, 1996
28. Schmoll H-J, Buchele T, Grothey A, Dempke W: Where do we stand with 5-fluorouracil? Semin Oncol 26: 589-605, 1999
29. Iyer L, Ratain MJ: 5-Fluorouracil pharmacokinetics: Causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 17: 494-506, 1999
30. Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Stafford S, Waterfield B, Matthews S, Lathia C, Schwartz B, Seymour L: An NCIC-CTG Phase I Dose Escalation Pharmacokinetic Study of the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Combination with Doxorubicin. (manuscript submitted to Invest New Drugs)
31. Tolcher A, Rowinsky EK, Rizzo J, Britten C, Siu L, Humphrey R, Smetzer L, Sorenson M, Von Hoff DD, Eckhardt SG: A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with paclitaxel and carboplatin. (Abstract) Proc ASCO 18: 160a, 1999